PCOS: Clinical Diagnosis, Rotterdam Criteria, and Metabolic Management

Demystifying Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) affects an estimated 8% to 13% of women of reproductive age worldwide, and up to 20% in Indian clinical cohorts. Far from being a simple ovarian issue, PCOS is a systemic neuro-endocrine and metabolic condition.

The Rotterdam Diagnostic Criteria

A clinical diagnosis requires meeting at least two of the three standardized Rotterdam criteria, once other etiologies (such as hyperprolactinemia, thyroid dysfunction, and congenital adrenal hyperplasia) are excluded:

1. Oligo- or Anovulation: Irregular menstrual cycles (>35 days apart), infrequent periods, or amenorrhea (absence of menses).
2. Clinical or Biochemical Hyperandrogenism: Elevated circulating testosterone/DHEAS, or clinical signs such as hirsutism (excessive facial/body hair), persistent cystic acne, or androgenic alopecia.
3. Polycystic Ovarian Morphology (PCOM): High-resolution pelvic ultrasound demonstrating $\ge 20$ follicles per ovary and/or ovarian volume $>10\text{ mL}$.

The Central Role of Insulin Resistance

Over 70% of individuals with PCOS have cellular insulin resistance, independent of Body Mass Index (BMI). When cells become resistant to insulin, the pancreas compensates by secreting higher levels of insulin (hyperinsulinemia). This excess insulin:

• Directly stimulates the ovarian theca cells to overproduce androgens.
• Suppresses hepatic production of Sex Hormone-Binding Globulin (SHBG), increasing free, bioactive testosterone.
• Impairs follicular maturation, resulting in anovulation.

Clinical Management Strategies

Evidence-based care prioritizes holistic and individualized therapeutic interventions:

• Metabolic Support: Targeted nutritional interventions focusing on low-glycemic index foods, adequate protein, and daily resistance training to enhance insulin receptor sensitivity.
• Myo-Inositol & D-Chiro-Inositol: Clinical ratios (40:1) have demonstrated improvements in ovulatory regularity and metabolic markers in double-blind trials.
• Endocrine Stabilization: Tailored medical therapies including cyclic progestins, combined contraceptives, or metformin under direct endocrinology supervision.